Silexion Therapeutics (NASDAQ: SLXN) Announces Path-Breaking Data for SIL204: Stock Soars 30%
For biotech companies, the return of positive data about any of their products under development leads to considerable attention, and hence, the Silexion Therapeutics Corp. (NASDAQ: SLXN) stock could be the one to watch this week. The company came into focus yesterday, and the stock rallied by 30% after it provided such an update about SIL204.
The Breakthrough
In the news release, Silexion Therapeutics announced that the data from the orthotopic pancreatic cancer models had been positive and demonstrated that when subcutaneously administered, SIL204 reduced both primary tumor growth and metastatic spread effectively. The company noted that it was a pathbreaking development and displayed considerable improvement when compared to data that had been reported previously.
Further Information
The data provided further proof of the efficacy of the company’s product in the considerably more relevant orthotopic settings in the clinical testing context. The company went on to note in its announcement that the results from the study constituted a major breakthrough and leap forward in the development program. As a result of the latest positive results, Silexion Therapeutics announced that it was also exploring the option of an expanded development program.
Management Quote
“These orthotopic model results represent a pivotal advancement in our development program,” said Mitchell Shirvan, Ph.D., CSO of Silexion. “While our previous data showed SIL204’s ability to reduce tumor growth in standard models, these new findings provide initial validation of its potential effectiveness in a much more clinically relevant setting. Particularly exciting is the demonstration that SIL204 can significantly reduce metastatic spread when administered subcutaneously, suggesting potential for treating both primary and metastatic disease with a minimally invasive delivery method.”
Technicals
| +/- EMA(20) | 1.2 (+20.83%) |
| +/- SMA(50) | 1.51 (-3.97%) |
| +/- SMA(200) | 35.73 (-95.94%) |
| 5-Day Perf. | +26.09% |
| 1-Month Perf. | +5.84% |
| 3-Month Perf. | -53.23% |
| 6-Month Perf. | -81.48% |
| YTD Perf. | -27.86% |
| 1-Year Perf. | -98.55% |
| RSI(14) | 54.02 |
| ATR(14) | 0.3 |
| ADX(14) | 19.23 |
| Beta (5Y) | 0.16 |